Mu.Ta.Lig - COST ACTION CA15135

Dr. Vladimir DOBRICIC

14 June 2016


General information

Name: Vladimir
Surname: Dobričić
Cell phone number with international prefix: +381665377577
Country: Serbia
Affiliation: Department of Pharmaceutical Chemistry, University of Belgrade – Faculty of Pharmacy
Gender: F □ M T
Year of the PhD title: 2014
Personal web page:
Previous COST participation: No T Yes □


List of 10 selected publications within last 5 years

1. Janković J, Djekic Lj, Dobričić V, Primorac M. Evaluation of critical formulation parameters in design and differentiation of self-microemulsifying drug delivery systems (SMEDDSs) for oral delivery of acyclovir. Int J Pharm 2016, 497, 301-311
2. Janićijević J,Krajišnik D, Čalija B, Nedić Vasiljević B, Dobričić V, Daković A, Antonijević MD, Milić J. Modified local diatomite as potential functional drug carrier – a model study for diclofenac sodium. International Journal of  Pharmaceutics, 2015 496, 466-474.
3. Dobričić V, Francuski B.M, Jaćević V, Rodić M.V,  Vladimirov S, Čudina O, Francuski Dj. Synthesis, crystal structure and local anti-inflammatory activity of L-phenylalanine methyl ester derivative of dexamethasone-derived cortienic acid, Journal of the Serbian Chemical Society, 2015, 80, 1481-1488.
4. Krstić M, Popović M, Dobričić V, Ibrić S. Influence of solid drug delivery system formulation on poorly water-soluble drug dissolution and permeability. Molecules 2015, 20, 14684-14698
5. Vucicevic J, Nikolic K, Dobričić V, Agbaba D. Prediction of blood – brain barrier permeation of α-adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis. European Journal of Pharmaceutical Sciences 2015, 68, 94-105
6. Dobričić V, Marković B, Milenković N, Savić V, Jaćević V, Rančić N, Vladimirov S, Čudina O. Design, synthesis and local anti-inflammatory activity of 17b-carboxamide derivatives of glucocorticoids. Archiv der Pharmazie 2014, 347, 786-797
7. Dobričić V, Nikolic K, Vladimirov S, Čudina O. Biopartitioning micellar chromatography as a predictive tool for skin and corneal permeability of newly synthesized 17b-carboxamide steroids. European Journal of Pharmaceutical Sciences 2014, 56, 105-112
8. Dobričić V, Marković B, Nikolic K, Vladimirov S, Čudina O. 17b-carboxamide steroids – in vitro prediction of human skin permeability and retention using PAMPA technique. European Journal of Pharmaceutical Sciences 2014, 52, 95-108
9. Krajišnik D, Daković A, Malenović A, Djekić Lj, Kragović M,  Dobričić V, Milić J. An investigation of diclofenac sodium release from cetylpyridinium chloride-modified natural zeolite as a pharmaceutical excipient. Microporous and Mesoporous Materials 2013, 167, 94-101
10. Markovic B, Dobricic V, Vladimirov S, Cudina O, Savic V, Karljikovic-Rajic K.  Investigation of solvolysis kinetics of new synthesized fluocinolone acetonide C-21 esters-an in vitro model for prodrug activation. Molecules 2011, 16, 2568-2671


Main skills and expertise (up to 5)

1.      Drug design (molecular docking and QSAR analysis)
2.      Drug synthesis
3.      Evaluation of permeability through biological membranes using in vitro techniques
4.      HPLC and LC-MS/MS analysis of drug substances and pharmaceutical formulations


Main equipment/facilities available in the participants’ lab (up to 5)

1.      Parallel Artificial Membrane Assay (PAMPA) models for the in vitro predicton of permeability of drugs through biological membranes
2.      Drug design softwares (ChemBioOffice Pro13, Gaussian09W, Simca 12+P, Dragon 6.0, Pentacle 1.0.6, FLAP 2.0.2 , ADMET Predictor, AutoDock Vina 1.1.2, Gold 5.4.0)
3.      Triple quadrupole mass spectrometer with a heated electrospray ionization
4.    NMR spectrometer (400 MHz)
5.  Electrochemical biosensor (DNA-modified electrodes) for the simulation of interaction of drugs with DNA



Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

Main research activities of our group within the CA15135 action will include:


-Design of novel multi-target ligands by use of molecular docking studies, quantitative-structure activity relationship analysis (3D-QSAR), pharmacophore modelling, virtual screening methods (ligand-based  and structure-based virtual screening) and in silico ADMET studies;


-Development of novel acridine derivatives with potential antiproliferative activity, based on the dual enzyme inhibition (src and MEK kinases, VEGFR-2 and src kinase);


-Development of novel non-steroidal compounds with potential antiproliferative activity, based on the dual inhibition of aromatase and steroid-sulfatase;


-Application of in vitro PAMPA and biopartitioning micellar chromatography models (developed in our lab) for the assessment of permeability through biological membranes (gastrointestinal tract, skin and blood-brain barrier);


-Development of electrochemical biosensor (DNA-modified electrodes) for the simulation of interaction of drugs with DNA.


Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 1
WG2: Selection of biological targets and assessment of biological data 4
WG3: Development of chemical databases 3
WG4: Development of Computational methods for multiple ligand design and discovery 2